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Sarco/endoplasmic reticulum calcium-ATPase (SERCA) is a membrane bound 22 cytosolic enzyme that is known to regulate the uptake of calcium into the 23 sarco/endoplasmic reticulum. Herein, we demonstrate for the first time that SERCA can 24 also regulate paramyxovirus [Peste des petits ruminants virus (PPRV) time-of-addition and virus step-specific assays, it was observed that Thapsigargin 31 specifically inhibits viral entry and subcellular localization of the viral proteins. 32
Furthermore, NDV, but not PPRV acquired a significant resistance to Thapsigargin on 33 long-term passage (P=70) in Vero cells. To the best of our knowledge, this is the first 34 report describing virus supportive role of SERCA and a rare report suggesting that 35 viruses may acquire resistance even in the presence of an inhibitor that targets a cellular 36 factor. This study will contribute in understanding paramyxovirus replication and 37
INTRODUCTION 43
The control strategies against pathogens have classically relied upon targeting 44 essential proteins of the pathogens (1). High mutation rate in viral genome allows the 45 virus to become resistant to antiviral drugs and preexisting immunity (2). Classically, 46 antiviral drugs have been developed by directly targeting viral proteins (3). Due to high 47 mutation rates, virus gets mutations at the druggable targets and becomes resistant. The 48 rise in incidence of drug resistance has prompted a shift in the development of novel 49 antiviral drugs (4). Viruses are obligate intracellular parasites that are highly dependent 50 on host. Host responses are equally important in determining actual outcome of the 51 diseases. Upon viral infection, numerous cellular factors are dysregulated (increased or 52 decreased expression); some of these host factors facilitate virus replication (proviral), 53 whereas others may have antiviral function (5). Proviral host factors may serve as 54 targets for development of novel antiviral therapeutics (1, 6, 7) . 55 8 for 96 h. However, at higher concentrations (>2 µM), it was found to be toxic to the 162 cells. A non-cytotoxic concentration (0.5 µM) of Thapsigargin was used thereafter. 163
In order to determine the in vitro antiviral efficacy of Thapsigargin, we 164 measured the yield of infectious PPRV/NDV/BHV-1/BPXV in the presence of 0.5 µM 165 inhibitor or vehicle control (DMSO). Thapsigargin significantly inhibited 166 paramyxovirus viz; NDV (Fig. 1c), PPRV (Fig. 1d) replication. It also significantly 167 inhibited BHV-1 (Fig. 1e) but not BPXV (Fig. 1f) replication (DNA viruses), 168 suggesting its potent antiviral activity against paramyxoviruses and BHV-1 virus. 169
Furthermore, in order to determine whether the antiviral efficacy of 170
Thapsigargin against paramyxoviruses is partially due to direct inactivation of the cell 171 free virions, we incubated the infectious virions with either 0.5 µM or 5 µm 172
Thapsigargin for 1.5 h and subsequently tested the residual infectivity on Vero/MDBK 173 cells. Thapsigargin did not exhibit any virucidal effect on any of the prototype virus 174 tested (Fig. 1g) suggesting that the antiviral activity of Thapsigargin is due to the 175 inhibitory effect on virus replication in the target cells. 176 SERCA facilitates paramyxovirus replication. In order to further confirm the 177 role of SERCA in virus replication, HeLa/goat kidney cells were transfected with 178 plasmid expressing SERCA2 (pCR3-SERCA2), followed by viral infection. As 179 compared to control plasmid (empty vector)-transfected cells, overexpression of 180 SERCA2 not only facilitated NDV/PPRV replication, but also rescued the inhibitory 181 effect of Thapsigargin on virus replication suggesting that SERCA2 supports 182 paramyxovirus replication (Fig. 2a and 2b) .
expression. PPRV infection of Vero cells resulted in enhanced SERCA2 expression. As 186 compared to mock-infected cells, a significant induction in SERCA2 expression was 187 observed at 3 hpi, which remained at the peak level between 24-72 hpi, before started 188 declining at 96 hpi (Fig. 3a, upper panel) . However, the levels of house keeping 189 control gene (GAPDH) were similar at all the time points, suggesting that the enhanced 190 levels of SERCA2 expression were related to viral infection (Fig. 3a, lower panel) . 191
Besides, we also observed that virus-induced SERCA2 expression could be blocked by 192
Thapsigargin treatment (Fig. 3b) . we observed cytoplasmic foci in majority of Thapsigargin-treated cells (Fig. 6a and  228 6b). Contrary, in majority of the DMSO-treated cells, virions were found to be 229 localized at the cell surface (Fig. 6a and 6b) . Further, the cells with normal (cell 230 surface) or defective (cytoplasmic foci) localization were quantified. Thapsigargin 231 treatment showed defective localization in ~70% of the cells, as compared to DMSO 232 control wherein this proportion was 10-30 % (Fig. 6c and 6d) (Fig. 7a) . However, resistance began appearing at ~P25 and 241 significant resistance was observed at P35 (~100 fold-inhibition compared to ~10,000 242 fold inhibition at zero passage) after which it became stable without acquiring complete 243 resistance (Fig. 7a) . Fluctuations in the overall viral titers and hence variation in fold 244 inhibition was observed (Fig. 7a) , which might be due to the fact that the harvest time 245
(72-120 h) and MOI (0.01-0.001) used was not similar at each passage. Therefore, we 246 carried out an experiment wherein a similar MOI (MOI=0.1) and harvest time (24 h) 247 was used to evaluate the relative resistance in Thapsigargin-passaged and control-248 passaged viruses. As compared to P0 and P70-Control viruses, P70-Thapsigargin virus 249 exhibited significantly lower sensitivity to Thapsigargin, though a completely resistant 250 phenotype could not be observed (Fig. 7b) . However, all PPRVs (P0, P70-Thapsigargin 251 and P70-Control) revealed similar sensitivity to Thapsigargin even at passage level 70 252 (Fig. 7c) , suggesting that PPRV is unlikely to develop Thapsigargin resistant mutants 253 upon long-term passage. Control-passaged viruses did not exhibit any significant 254 resistance against Thapsigargin even upon 70 passages ( Fig. 7b and 7c) suggesting that 255 resistance against Thapsigargin (NDV) is not a general phenomenon due to sequential 256 high passages but rather a specific event acquired in presence of Thapsigargin. 257
High mutation rate in RNA viruses induces resistance to antiviral drugs and 259 preexisting immunity. The rise in incidence of drug resistance has prompted a shift 260 towards the development of novel antiviral drugs. As compared to the viral genome, 261 genetic variability of the host is quite low and therefore host-targeting agents are 262 considered to impose a higher genetic barrier to generation of resistant viruses (24, 27-263 29) . Thus, a potentially better approach for development of novel antiviral therapeutics 264 would be to target host factors required for viral replication. Targeting host factors 265 could have a significant impact on multiple virus genotypes (strain/serotype) and 266 provide broad spectrum inhibition against different families of viruses which might use 267 the same cellular pathway(s) for replication (24, (30) (31) (32) (33) . This novel approach has led to 268 the development of some promising compounds for treatment of HCV and HIV (34, 269 35 
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Arruda Thapsigargin-free medium for 1h at 4 o C to permit attachment, followed by washing and addition of fresh medium containing Thapsigargin or vehicle-control. Entry was allowed to proceed at 37 o C for 1h after which the cells were washed again with PBS to remove any extracellular viruses and incubated with cell culture medium without any inhibitor.
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Evaluation of Thapsigargin resistance in NDV

